Positive Interim results of phase IIa trial for FG001 in head and neck cancer, presented as a case reports at the World Molecular Imaging Congress

FluoGuide A/S is delighted with the preliminary findings from the FG001 study concerning cancer surgery guidance in head & neck cancer patients, showcased at the 2023 World Molecular Imaging Congress in Prague. The presentation includes a patient case.

👇Please click on the image below to directly access the latest data (R&D Status | Core Patent | Clinical Trial | Approval status in Global countries) of this drug.

The showcased poster titled, "Optical-Guided Surgery in Patients with Oral and Oropharyngeal Squamous Cell Carcinoma Using a unique uPAR-targeting Near-Infrared Imaging Agent FG001: An Explorative Phase II Clinical Trial - a Case Example", discusses a consummate example from the phase IIa investigation of FG001 in those diagnosed with head & neck cancer.

It underscore the precision of FluoGuide’s uPAR-targeting imaging agent FG001, specifically when used for detecting oral squamous cell carcinoma. The poster extrapolates on the encouraging preliminary data obtained from the phase IIa research on FG001 in those suffering from head & neck cancer, the primary outcomes of which are presumed to be publicized in H2 2023.

"We are gratified by the positive data being presented and are looking forward to the topline results as well as presentation of the complete results of the trial later this year," states Andreas Kjær, CSO.

👇Please click on the picture link below for free registration or login directly if you have freemium accounts, you can browse the latest research progress on drugs, indications, organizations, clinical trials, clinical results, and drug patents related to this target.

According to the data provided by the Synapse Database, As of September 12, 2023, there are 13 investigational drugs for the uPAR target, including 19 applicable indications,12 R&D institutions involved, with related clinical trials reaching 11，and as many as 3101 patents.

Head and neck cancer includes cancers in the lining of the lips, tung, mouth, or upper throat. Head and neck cancers is often occurring in close anatomical proximity to small vital structures such as blood vessels supplying the brain and many important nerves. Roche Holding AG, Bristol Myers Squibb Co., and Nippon Kayaku Co., Ltd. are the leading companies in terms of drug development for Head and Neck Neoplasms. The most targeted molecules include DNA, PD-1, TYMS, Tubulin, and EGFR. Future development in this indication is expected to focus on further advancements in these areas and potentially explore new targets and drug types.